Private companies own 43% of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) shares but retail investors control 46% of the company

Key Insights

  • The considerable ownership by retail investors in Tianjin Pharmaceutical Da Ren Tang Group indicates that they collectively have a greater say in management and business strategy

  • The top 14 shareholders own 50% of the company

  • Past performance of a company along with ownership data serve to give a strong idea about prospects for a business

Every investor in Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) should be aware of the most powerful shareholder groups. We can see that retail investors own the lion's share in the company with 46% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

Private companies, on the other hand, account for 43% of the company's stockholders.

Let's take a closer look to see what the different types of shareholders can tell us about Tianjin Pharmaceutical Da Ren Tang Group.

See our latest analysis for Tianjin Pharmaceutical Da Ren Tang Group

ownership-breakdown
SGX:T14 Ownership Breakdown November 13th 2023

What Does The Institutional Ownership Tell Us About Tianjin Pharmaceutical Da Ren Tang Group?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

As you can see, institutional investors have a fair amount of stake in Tianjin Pharmaceutical Da Ren Tang Group. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Tianjin Pharmaceutical Da Ren Tang Group, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
SGX:T14 Earnings and Revenue Growth November 13th 2023

We note that hedge funds don't have a meaningful investment in Tianjin Pharmaceutical Da Ren Tang Group. Looking at our data, we can see that the largest shareholder is Jinhushen Biomedical Technology Co., Ltd. with 43% of shares outstanding. With 1.0% and 0.9% of the shares outstanding respectively, National Council for Social Security Fund and GF Fund Management Co., Ltd. are the second and third largest shareholders.

A closer look at our ownership figures suggests that the top 14 shareholders have a combined ownership of 50% implying that no single shareholder has a majority.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.